CoChat

Convergent Evolution of Escape from Hepaciviral Antagonism in Primates

Open access

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

The ability to mount an interferon response on sensing viral infection is a critical component of mammalian innate immunity. Several viruses directly antagonize viral sensing pathways to block activation of the host immune response. Here, we show that recurrent viral antagonism has shaped the evolution of the host protein MAVS--a crucial component of the viral-sensing pathway in primates. From sequencing and phylogenetic analyses of MAVS from 21 simian primates, we found that MAVS has evolved under strong positive selection. We focused on how this positive selection has shaped MAVS' susceptibility to Hepatitis C virus (HCV). We functionally tested MAVS proteins from diverse primate species for their ability to resist antagonism by HCV, which uses its protease NS3/4A to cleave human MAVS. We found that MAVS from multiple primates are resistant to inhibition by the HCV protease. This resistance maps to single changes within the protease cleavage site in MAVS, which protect MAVS from getting cleaved by the HCV protease. Remarkably, most of these changes have been independently acquired at a single residue 506 that evolved under positive selection. We show that "escape" mutations lower affinity of the NS3 protease for MAVS and allow it to better restrict HCV replication. We further show that NS3 proteases from all other primate hepaciviruses, including the highly divergent GBV-A and GBV-C viruses, are functionally similar to HCV. We conclude that convergent evolution at residue 506 in multiple primates has resulted in escape from antagonism by hepaciviruses. Our study provides a model whereby insights into the ancient history of viral infections in primates can be gained using extant host and virus genes. Our analyses also provide a means by which primates might clear infections by extant hepaciviruses like HCV.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pbio.1001282

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 MAVS has evolved under positive selection in primates. (A) dN/dS ratios for the MAVS gene, calculated using free-ratio model in PAML, are shown on a phylogeny [26] along with common and scientific names of the primate species represented. Branches with dN/dS ratios greater than 1 are highlighted in red. For branches that did not experience any synonymous (S) changes, number of nonsynonymous (N) and S changes are shown in parentheses. (B) Residues identified as being under recurrent positive selection are indicated on a schematic of the MAVS protein, including the CARD, Proline-rich, and transmembrane (TM) domains. CodeML program of PAML software was used to identify sites under positive selection by comparing M7 (beta) versus M8 (beta & ω) models, assuming codon frequencies according to the F61 model. Web-based implementation of HyPhy package was used to perform REL analysis. We present only those sites identified with a posterior probability higher than 0.9 in both Bayes empirical Bayes (BEB) and random effects likelihood (REL) methods.
Figure 1 MAVS has evolved under positive selection in primates. (A) dN/dS ratios for the MAVS gene, calculated using free-ratio model in PAML, are shown on a phylogeny [26] along with common and scientific names of the primate species represented. Branches with dN/dS ratios greater than 1 are highlighted in red. For branches that did not experience any synonymous (S) changes, number of nonsynonymous (N) and S changes are shown in parentheses. (B) Residues identified as being under recurrent positive selection are indicated on a schematic of the MAVS protein, including the CARD, Proline-rich, and transmembrane (TM) domains. CodeML program of PAML software was used to identify sites under positive selection by comparing M7 (beta) versus M8 (beta & ω) models, assuming codon frequencies according to the F61 model. Web-based implementation of HyPhy package was used to perform REL analysis. We present only those sites identified with a posterior probability higher than 0.9 in both Bayes empirical Bayes (BEB) and random effects likelihood (REL) methods.CC BY · PubMed Central
Figure 2 MAVS from multiple primate species is resistant to antagonism by HCV protease NS3/4A. (A) Induction of IFN-β promoter, as measured by luciferase firefly activity, upon expression of MAVS cDNA from corresponding species coexpressed with (+) or without (−) HCV NS3/4A. Primates with MAVS capable of significant IFN-β induction even in the presence of HCV protease are highlighted in bold. Human (C508R) refers to substitution of Cysteine (C) at position 508 with Arginine (R) in human MAVS. Firefly luciferase activity is normalized as being 100% for MAVS from each species in absence of HCV NS3/4A. All experiments are done in triplicates, and error bars indicate standard deviation. (B) Amino acid sequence of MAVS (residues 503–514) from corresponding primates in (A). The scissor icon indicates HCV NS3/4A cleavage site. The P positions for the HCV protease are indicated at the bottom of the alignment. Arginine (R) at residue 508 in olive baboon, believed to prevent MAVS cleavage, is boxed and the C508R change in human MAVS is underlined. Position 506, highlighted in bold, correlates with the ability of primate MAVS to induce IFN-β even in the presence of HCV NS3/4A protease as seen in (A). Changes away from the ancestral valine (V) at position 506 are indicated in red.
Figure 2 MAVS from multiple primate species is resistant to antagonism by HCV protease NS3/4A. (A) Induction of IFN-β promoter, as measured by luciferase firefly activity, upon expression of MAVS cDNA from corresponding species coexpressed with (+) or without (−) HCV NS3/4A. Primates with MAVS capable of significant IFN-β induction even in the presence of HCV protease are highlighted in bold. Human (C508R) refers to substitution of Cysteine (C) at position 508 with Arginine (R) in human MAVS. Firefly luciferase activity is normalized as being 100% for MAVS from each species in absence of HCV NS3/4A. All experiments are done in triplicates, and error bars indicate standard deviation. (B) Amino acid sequence of MAVS (residues 503–514) from corresponding primates in (A). The scissor icon indicates HCV NS3/4A cleavage site. The P positions for the HCV protease are indicated at the bottom of the alignment. Arginine (R) at residue 508 in olive baboon, believed to prevent MAVS cleavage, is boxed and the C508R change in human MAVS is underlined. Position 506, highlighted in bold, correlates with the ability of primate MAVS to induce IFN-β even in the presence of HCV NS3/4A protease as seen in (A). Changes away from the ancestral valine (V) at position 506 are indicated in red.CC BY · PubMed Central
Figure 3 Changes at residue 506 in MAVS protect it from cleavage by HCV NS3/4A protease. (A) Normalized induction of IFN-β promoter by MAVS variants with the indicated changes, as measured by luciferase firefly activity, is presented in the presence or absence of HCV NS3/4A protease. Evolutionary changes in amino acid at position 506 are highlighted in red. Firefly activity is normalized to be 100% in absence of HCV NS3/4A. Experiments are done in triplicates, and error bars indicate standard deviation. (B) Immunoblot analysis showing MAVS, NS3/4A, and actin protein from cells expressing the MAVS variant with or without NS3/4A according to corresponding labeling in (A). The human V506G MAVS variant was expressed at low levels and is therefore shown at higher exposure (marked by dotted lines). Lowest size bands are non-specific in these samples. (C) Co-immunoprecipitation analysis of MAVS with the single-chain (SC) HCV NS3/4A protease containing the protease active site mutation S1165A. Extracts from HEK 293 cells expressing Flag-tagged human MAVS with either valine or glycine (in red) at position 506 and Myc-SC-NS3 (S1165A) were immunoprecipitated using Flag-conjugated beads followed by immunoblot analysis.
Figure 3 Changes at residue 506 in MAVS protect it from cleavage by HCV NS3/4A protease. (A) Normalized induction of IFN-β promoter by MAVS variants with the indicated changes, as measured by luciferase firefly activity, is presented in the presence or absence of HCV NS3/4A protease. Evolutionary changes in amino acid at position 506 are highlighted in red. Firefly activity is normalized to be 100% in absence of HCV NS3/4A. Experiments are done in triplicates, and error bars indicate standard deviation. (B) Immunoblot analysis showing MAVS, NS3/4A, and actin protein from cells expressing the MAVS variant with or without NS3/4A according to corresponding labeling in (A). The human V506G MAVS variant was expressed at low levels and is therefore shown at higher exposure (marked by dotted lines). Lowest size bands are non-specific in these samples. (C) Co-immunoprecipitation analysis of MAVS with the single-chain (SC) HCV NS3/4A protease containing the protease active site mutation S1165A. Extracts from HEK 293 cells expressing Flag-tagged human MAVS with either valine or glycine (in red) at position 506 and Myc-SC-NS3 (S1165A) were immunoprecipitated using Flag-conjugated beads followed by immunoblot analysis.CC BY · PubMed Central
Figure 4 Protease-resistant MAVS better restricts HCV replication. Immunoblot showing HCV NS5A protein from lysates of Huh7-K2040 cells transiently transfected with control plasmid (vector alone), human, or rhesus MAVS variants with indicated mutations. The amount of HCV restriction achieved by indicated MAVS variant is quantified below the Western blot.
Figure 4 Protease-resistant MAVS better restricts HCV replication. Immunoblot showing HCV NS5A protein from lysates of Huh7-K2040 cells transiently transfected with control plasmid (vector alone), human, or rhesus MAVS variants with indicated mutations. The amount of HCV restriction achieved by indicated MAVS variant is quantified below the Western blot.CC BY · PubMed Central
Figure 5 NS3 proteases from distantly related GB viruses inhibit human MAVS. (A) Phylogram made using NS3 sequence from the indicated viruses. Bootstrap values are indicated for each branch. Scale represents 0.1 amino acid substitutions per site. Bovine viral diarrheal virus (BVDV) and Yellow fever virus (YFV) are representative pesti- and flaviviruses, respectively. We refer to GBV-C and GBV-A viruses as hepaciviruses, although they have not been formally assigned to a particular genus within the Flaviviridae family. GBV-C is also known as Hepatitis G virus (HGV). CHV stands for canine hepacivirus [17]. Corresponding hosts that can be naturally infected by each virus are indicated on the right. (B) IFN-β induction, as determined by luciferase firefly activity upon expression of human MAVS in the presence of NS3 protease from the corresponding virus in (A). IFN-β induction is normalized as being 100% in absence of any protease. Experiments were performed in triplicate with error bars indicating standard deviation.
Figure 5 NS3 proteases from distantly related GB viruses inhibit human MAVS. (A) Phylogram made using NS3 sequence from the indicated viruses. Bootstrap values are indicated for each branch. Scale represents 0.1 amino acid substitutions per site. Bovine viral diarrheal virus (BVDV) and Yellow fever virus (YFV) are representative pesti- and flaviviruses, respectively. We refer to GBV-C and GBV-A viruses as hepaciviruses, although they have not been formally assigned to a particular genus within the Flaviviridae family. GBV-C is also known as Hepatitis G virus (HGV). CHV stands for canine hepacivirus [17]. Corresponding hosts that can be naturally infected by each virus are indicated on the right. (B) IFN-β induction, as determined by luciferase firefly activity upon expression of human MAVS in the presence of NS3 protease from the corresponding virus in (A). IFN-β induction is normalized as being 100% in absence of any protease. Experiments were performed in triplicate with error bars indicating standard deviation.CC BY · PubMed Central
Figure 6 Protective effect of changes at residue 506 on antagonism by GB virus proteases. IFN-β induction resulting from expression of MAVS from indicated species, as determined by luciferase firefly activity, is presented for either the ancestral “susceptible” valine (light grey) or derived “resistant” variants (dark grey) at position 506 as shown. Luciferase firefly activity is normalized as being 100% in absence of the protease for each MAVS variant. Susceptibility to each of the GB-virus protease is shown. x- and y-axes are the same for all graphs. All experiments were performed in triplicate with error bars indicating standard deviation.
Figure 6 Protective effect of changes at residue 506 on antagonism by GB virus proteases. IFN-β induction resulting from expression of MAVS from indicated species, as determined by luciferase firefly activity, is presented for either the ancestral “susceptible” valine (light grey) or derived “resistant” variants (dark grey) at position 506 as shown. Luciferase firefly activity is normalized as being 100% in absence of the protease for each MAVS variant. Susceptibility to each of the GB-virus protease is shown. x- and y-axes are the same for all graphs. All experiments were performed in triplicate with error bars indicating standard deviation.CC BY · PubMed Central
Figure 7 Mapping the adaptive change at site 506 in the Macaque lineage. Accepted Macaque phylogeny. Both species names and common names are shown. Amino acid at position 506 in MAVS is shown on the right. The escape variant glycine (G) is shown in red. Note that the outgroup Olive baboon has valine (V) at position 506. This indicates that the common ancestor of macaques underwent the adaptive change 5–8 million years ago. MYA, million years ago.
Figure 7 Mapping the adaptive change at site 506 in the Macaque lineage. Accepted Macaque phylogeny. Both species names and common names are shown. Amino acid at position 506 in MAVS is shown on the right. The escape variant glycine (G) is shown in red. Note that the outgroup Olive baboon has valine (V) at position 506. This indicates that the common ancestor of macaques underwent the adaptive change 5–8 million years ago. MYA, million years ago.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Fields B. N Knipe D. M Howley P. M 2007 Fields' virology Philadelphia Wolters Kluwer Health/Lippincott Williams & Wilkins 2 v. (xix, 3091, 3086 pp.)

Cited by

See all 96

Metadata

Authors
Patel, M. R., Loo, Y.-M., Horner, S. M., Gale, M., & Malik, H. S.
Affiliations
  • Fred Hutch Cancer Center (US)
  • University of Washington (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
Malik, Harmit S.
Venue
PLoS Biology
Published
2012-03-13
Volume
10
Issue
3
Pages
e1001282
ISSN
  • 1544-9173 (ISSN-L)
  • 1545-7885
OpenAlex
W2120167579
Cited by
95
References
53
Citations by year
2026: 2 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 6 · 2021: 7 · 2020: 7 · 2019: 5 · 2018: 8 · 2017: 7 · 2016: 4 · 2015: 11 · 2014: 6 · 2013: 16 · 2012: 8
FWCI
5.73
Type
journal article
Language
en
Open access
Locations
  • PLoS Biology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Science Foundation (CAREER)
  • Howard Hughes Medical Institute
  • Cancer Research Institute
  • National Institutes of Health (AI083019, AI88778, AI060389)
  • National Cancer Institute (P30CA015704)
  • National Institute of Allergy and Infectious Diseases (R01AI060389, U19AI083019, AI88778, R56AI060389, AI-060389, AI083019, U19AI088778)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
  • Health Sciences › Medicine › Hepatology › Hepatitis C virus research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Evolution and Genetic Dynamics
Keywords
MAVS, interferon response, viral antagonism, hepatitis C virus, NS3/4A protease, hepatitis G virus, positive selection, convergent evolution, viral sensing, host-virus coevolution, proteolytic cleavage sites
MeSH terms
Viral Proteases, Amino Acid Sequence, Animals, Genes, Viral, Hepatitis C, Humans, Models, Molecular, Molecular Sequence Data, Phylogeny, Primates, Selection, Genetic, Serine Endopeptidases, Virus Replication, Hepacivirus, Sequence Alignment, Viral Nonstructural Proteins, Evolution, Molecular, Nucleoside-Triphosphatase, Adaptor Proteins, Signal Transducing, DEAD-box RNA Helicases, Host-Pathogen Interactions, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.